Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @fdalawblog: New FDA Draft Guidance: Quality Considerations for Continuous Manufacturing - https://t.co/1cyB8EsDmX
SteveFDA (R-D.C.)
@SGottliebFDA
RT @hbottemiller: This morning at #wpc2019, @SGottliebFDA said he noticed NASDA is serving soy and almond milk w/coffee. He admitted… https://t.co/xmYALhA6FQ
SteveFDA (R-D.C.)
@SGottliebFDA
I’m coming up on @SquawkCNBC to discuss what #FDA is doing to promote drug competition and access; and our new steps to reduce opioid exposure and the rate of new addiction. Talking with @BeckyQuick and Sqawk team. https://t.co/qwtMlcpTZZ
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is issuing new draft guidance to help advance the continuous manufacturing of small molecules drugs. Our FY 2019 budget includes new resources to help efficiently advance these capabilities to improve drug manufacturing quality, safety, reliability. https://t.co/dMMcz5j2K8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: FDA created “This Is Our Watch” to give retailers the tools they need to comply with tobacco regulations and protec… https://t.co/e3PMVGiCdK
SteveFDA (R-D.C.)
@SGottliebFDA
Continuous manufacturing helps ensure consistently-made products, simplifies scaling operations to meet demand and promotes process reliability that can help reduce drug shortages. Today, we’ve issued new information for industry on CM: https://t.co/EmYQq4RpAq
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA, and Janet Woodcock, M.D., director of the Center for Drug Evaluation… https://t.co/Njw49w8dF5
SteveFDA (R-D.C.)
@SGottliebFDA
We’re taking new steps to help advance broader adoption of continuous manufacturing by providing guidance and information to interested companies, to help support CM for brand, generic and OTC drugs. https://t.co/EmYQq4RpAq https://t.co/ZVNL00H50s
SteveFDA (R-D.C.)
@SGottliebFDA
The Continuous Manufacturing guidance we issued today supports an internationally harmonized effort to promote broader adoption and approval of products that are manufactured using these modern processes for multiple geographic regions. https://t.co/EmYQq4RpAq
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDA_MCMi: FDA, CDC, and CMS launch task force to help facilitate rapid availability of diagnostic tests during public health… https://t.co/71YMrrGec6
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SeemaCMS: .@CMSGov, in partnership with @US_FDA & @CDCgov, is launching the Tri-Agency Task Force for Emergency Diagnostics t… https://t.co/VfkQiyJTnX
SteveFDA (R-D.C.)
@SGottliebFDA
FDA Plans Multifaceted Response to Opioid-Abuse Epidemic - WSJ https://t.co/xpz4ZXPJV8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: FDA developed two new youth vaping prevention posters for use by doctors, youth groups, churches, or state and loca… https://t.co/yV7Xk0y62i
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: LIVE NOW: #FDA Commissioner @SGottliebFDA testifies before the House Appropriations Subcommittee on Agriculture, Ru… https://t.co/oB4AO8hmjT
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: #FDAVoices #PatientVoices FDA’s Oncology Center for Excellence will co-sponsor the 4th public workshop on Measuring… https://t.co/0OZcyZKyHl
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDA_Drug_Info: Learn how FDA is modernizing clinical trials with master protocols in our latest issue of the CDER SBIA Chronicles:… https://t.co/pxg84okSWL
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: Rep. @BettyMcCollum04 asks Commissioner @SGottliebFDA about cosmetic safety during today’s hearing. https://t.co/yD4oZEit6x
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: FDA issued a draft guidance that explains the enforcement policy for manufacturers, importers or distributors of ce… https://t.co/tbQ8TEljGm
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDASpox: Read #FDAVoices about addressing the challenges of developing treatments for rare diseases – in 2018, FDA took step… https://t.co/dj0DW20JuL
SteveFDA (R-D.C.)
@SGottliebFDA
All drugs marketed in the U.S. must be manufactured to meet established quality standards that ensure every dose is safe and effective and free of contamination and defects. OPQ’s annual report provides details on the vital work that makes this happen. https://t.co/MY4I3JtK3o